# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Silvan Tuerkcan reiterates Vor Biopharma (NASDAQ:VOR) with a Market Outperform and maintains $12 pric...
Vor Biopharma reveals promising Phase 1/2 study results for AML treatment, and it is planning FDA pivotal trial discussions.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vor Biopharma (NASDAQ:VOR) with a Buy and maintains $17.5 ...
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33ALLO demons...
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrat...
Barclays analyst Carter Gould maintains Vor Biopharma (NASDAQ:VOR) with a Overweight and lowers the price target from $10 to...
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.42) ...